[go: up one dir, main page]

MX2018013762A - Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. - Google Patents

Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Info

Publication number
MX2018013762A
MX2018013762A MX2018013762A MX2018013762A MX2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A
Authority
MX
Mexico
Prior art keywords
cd40l
methods
fusion polypeptides
fusion protein
antibody
Prior art date
Application number
MX2018013762A
Other languages
English (en)
Inventor
Baca Manuel
Drabic Stacey
Emtage Peter
Herbst Ronald
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2018013762A publication Critical patent/MX2018013762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proporciona una proteína de fusión CD40L-Fc y métodos para usar la proteína de fusión en el tratamiento del cáncer que comprenden administrar la proteína de fusión CD40L-Fc o la proteína de fusión CD40L-Fc combinada con uno o más inhibidores de puntos de control inmunitario (por ejemplo, un anticuerpo anti-CTLA4 o anticuerpo anti-PD-L1).
MX2018013762A 2016-05-13 2017-05-12 Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. MX2018013762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13
PCT/US2017/032352 WO2017197231A1 (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018013762A true MX2018013762A (es) 2019-03-28

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013762A MX2018013762A (es) 2016-05-13 2017-05-12 Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Country Status (18)

Country Link
US (1) US10975155B2 (es)
EP (1) EP3455263A4 (es)
JP (1) JP2019523636A (es)
KR (1) KR20190004319A (es)
CN (1) CN109153729A (es)
AR (1) AR108468A1 (es)
AU (1) AU2017264944A1 (es)
BR (1) BR112018072953A2 (es)
CA (1) CA3022636A1 (es)
CL (1) CL2018003141A1 (es)
CO (1) CO2018013104A2 (es)
IL (1) IL262727A (es)
MA (1) MA44993A (es)
MX (1) MX2018013762A (es)
RU (1) RU2018138703A (es)
SG (1) SG11201809374VA (es)
TW (1) TW201741337A (es)
WO (1) WO2017197231A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2310509T1 (sl) * 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
KR20240056664A (ko) 2013-09-11 2024-04-30 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
DK3565828T3 (da) 2017-01-05 2022-02-21 Kahr Medical Ltd Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
WO2018127917A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
WO2020163534A1 (en) * 2019-02-06 2020-08-13 The Regents Of The University Of California Dominant negative cd40l polypeptides
EP3998282A4 (en) * 2019-07-08 2023-08-09 Progen Co., Ltd. NEW FUSION PROTEIN AND ITS USE
WO2021043955A1 (en) * 2019-09-05 2021-03-11 Astrazeneca Ab Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)
US20230048046A1 (en) * 2019-12-13 2023-02-16 Cugene Inc Novel interleukin-15 (il-15) fusion proteins and uses thereof
JP7645555B2 (ja) * 2020-01-23 2025-03-14 ジェネクシン・インコーポレイテッド Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途
IL298693A (en) * 2020-06-04 2023-02-01 Carisma Therapeutics Inc New structures for chimeric antigen receptors
EP4304629A4 (en) * 2021-03-12 2025-02-19 Janssen Biotech, Inc. Bioengineered immunomodulatory fusion protein compositions
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
CN120917139A (zh) 2023-04-05 2025-11-07 豪夫迈·罗氏有限公司 用于抗体表达细胞的体外培养方法
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN120888000A (zh) * 2025-07-31 2025-11-04 上海市胸科医院 Cd40l-il-2融合蛋白及其制备与在制备治疗肿瘤药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832229B1 (en) * 1995-06-07 2004-01-14 Immunex Corporation Cd40l mutein
NZ333602A (en) * 1996-07-08 2000-06-23 Biogen Inc Treatment of smooth muscle cell dependent disease using antibodies capable of inhibiting the CD40 - CD40 ligand interaction
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
EP1309705B1 (en) * 2000-07-25 2012-02-15 Immunomedics Inc. Multivalent target binding protein
JP4660092B2 (ja) * 2001-12-21 2011-03-30 イミユネツクス・コーポレイシヨン 組換えポリペプチド
HUE039846T2 (hu) * 2005-05-20 2019-02-28 Ablynx Nv Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
SI2310509T1 (sl) * 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白

Also Published As

Publication number Publication date
WO2017197231A1 (en) 2017-11-16
US10975155B2 (en) 2021-04-13
AR108468A1 (es) 2018-08-22
CN109153729A (zh) 2019-01-04
EP3455263A4 (en) 2020-01-01
JP2019523636A (ja) 2019-08-29
RU2018138703A (ru) 2020-06-15
EP3455263A1 (en) 2019-03-20
IL262727A (en) 2018-12-31
MA44993A (fr) 2019-03-20
US20170327588A1 (en) 2017-11-16
CO2018013104A2 (es) 2018-12-14
CA3022636A1 (en) 2017-11-16
SG11201809374VA (en) 2018-11-29
KR20190004319A (ko) 2019-01-11
BR112018072953A2 (pt) 2019-02-19
TW201741337A (zh) 2017-12-01
CL2018003141A1 (es) 2018-12-28
AU2017264944A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2024008677A (es) Conjugados de camptotecina.
IL278920A (en) ENTPD2 antibodies, combination therapies, and methods of using antibodies and combination therapies
MX2022008868A (es) Tratamiento del cancer con tg02.
PH12019501146A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
SG11201811724TA (en) Translation device and translation method
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
MY191944A (en) Binding proteins and methods of use thereof
MX382129B (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso.
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
HK1244681A1 (zh) 用於治疗肿瘤形成的治疗组合和方法
AU201816805S (en) Analyses device
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MX2021005377A (es) Terapias dirigidas a cdcp1.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
MX384037B (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
AU201816808S (en) Analyses device